secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001193125-25-175494
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics reports Q2 net loss $115.6M; PDUFA for paltusotine on Sept 25, 2025
-----------------------------------------------------------------------------

- Revenue $1.0M (vs $0.4M in Q2 2024); net loss widened to $115.6M from $74.1M YoY.
- Cash, cash equivalents & investments $1.2B as of June 30, 2025; expected runway into 2029.
- Paltusotine NDA PDUFA target action date September 25, 2025 for acromegaly; EMA review expected H1 2026.
- Upcoming Phase 3 starts in H2 2025 for paltusotine in carcinoid syndrome and atumelnant in CAH (adult and pediatric).
- 2025 cash used in operations guided at $340-370M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312525175494/0001193125-25-175494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312525175494/crnx-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-175494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer